PREPRINT
jkl keys enabled
640 views

Open Radical Cholecystectomy with Partial Hepatectomy for Gallbladder Cancer

Shoichi Irie, MD; Mamiko Miyashita, MD; Yu Takahashi, MD; Hiromichi Ito, MD

Cancer Institute Hospital, Gastrointestinal Cancer Center Division of Hepatobiliary and Pancreatic Surgery Cancer Institute Hospital Japanese Foundation for Cancer Research Ariake, Tokyo 135-8550

Abstract

Gallbladder cancer (GBCA) is a relatively uncommon disease with dismal prognosis. As the symptoms associated with GBCA are vague and non-specific, most patients present when the disease is at an advanced stage and the majority are diagnosed when the disease is beyond the possibility of resection. On the other hand, GBCA can be discovered incidentally and appropriate oncologic surgery provides a great chance of cure for patients with GBCA. We presented a case of incidentally-diagnosed GBCA and described the surgical management for operable GBCA with a focus on the operative technique and perioperative management. A 60 man presented with incidentally-discovered GBCA during a follow-up imaging study for his previously treated bladder cancer. The patient had been asymptomatic, and CT showed a growing mass in the gallbladder without evidence of metastatic disease. GBCA was suspected, and resection was recommended. He underwent extended cholecystectomy including cholecystectomy enbloc with partial hepatectomy at segment 4B and 5 and portal lymphadenectomy. His postoperative course was uneventful, and histologic examination confirmed the diagnosis of GBCA, pT3N1M0, stage IIIB.

Case Overview

Background

The patient is a 60-year-old man who presented with gallbladder mass. The mass was discovered during regular follow-up for recently treated bladder cancer. He underwent total cystectomy with ileal conduit following neoadjuvant chemotherapy two years prior and had been followed by serial CT scan every 6 months. The most recent CT showed gallbladder mass which had been growing compared with the prior scan 6 months before. Thus, gallbladder cancer was suspected, and resection was recommended.

Physical Exam

The patient was asymptomatic and did not have any specific findings on physical exam. His abdomen was soft and flat with well healed scar at the lower midline and ileal conduit at the right lower quadrant.

Imaging

CT showed a 2-cm mass at the fundus gallbladder, consistent with GBCA. It was contrast-enhanced and there was no definitive sign of liver invasion, lymphadenopathy or distant metastasis. MRI ruled out liver metastasis.

Options for Treatment

For patients with suspected gallbladder cancer like the patient shown here, surgical resection should be considered when the staging work-up does not detect the evidence of metastatic disease. Unlike other types of gastrointestinal cancer which can be accessible endoscopically, histologic confirmation by biopsy is usually unavailable and thus thorough explanation to the patient about the possibility that the suspected lesions may turn out to be benign in the histopathologic examination after radical operation is critical. The standard oncologic resection includes cholecystectomy en bloc with partial liver resection (around the gallbladder fossa) and portal lymphadenectomy. The resection of common bile duct is necessary only when it is involved by the tumors by preoperative imaging studies or the cystic duct stump margin is proved positive for cancer by intraoperative frozen section. Laparoscopic cholecystectomy should be avoided when cancer is highly suspected preoperatively because of the risk of violation of the plane between the tumor and the liver, and the risk of port site seeding. On the other hand, if the preoperative diagnosis is unclear, initial laparoscopic cholecystectomy is a reasonable option for diagnostic purpose. When the diagnosis of GBCA is histologically confirmed, additional partial liver resection and lymphadenectomy (either open or laparoscopically depending on the surgeon’s skill and expertise) should be completed simultaneous to cholecystectomy or as the separate staged operation later.

Rationale for Treatment

Our patient had a gallbladder mass that kept growing in the past several months and gallbladder cancer was highly suspected. As there was no metastatic disease detected on the preoperative imaging studies including CT and MRI, resection was planned without confirming histological diagnosis.

When the patient has elevated tumor marker CA19-9, staging laparoscopy has been shown to have a high yield to identify the occult metastatic disease and to allow the patients to avoid non-beneficial laparotomy.3 The serum CA19-9 level for our patient was within normal range and staging laparoscopy was not performed.

The goal of oncologic surgery is to remove all cancer cells potentially spread in the regional area and thus definitive resection for GBCA should include not only gallbladder, but also part of the liver bed around the gallbladder fossa (segment 4B and 5 at least) and all regional lymph nodes around the hepatoduodenal ligament and retro-pancreatic area (#8, 12, 13 lymph node stations). Bile duct resection was not performed for this patient as the tumor was located away from the neck and the cystic duct margin was proved negative for cancer.

Because of its propensity to spread to regional lymph nodes at an early stage and high rate of locoregional recurrence, adjuvant chemotherapy and/or chemoradiotherapy seems a rational therapeutic option for patients with GBCA. However, the rarity of gallbladder cancer and further limitation of patients who can undergo complete resection makes the randomized trial difficult to conduct and data to support its efficacy remains limited. While there is no conclusive evidence for the efficacy of adjuvant chemotherapy to date, chemotherapeutic regimen with combination of gemcitabine and cisplatin is often used for selected patients with high risk of recurrence (such as patients with N1 disease) as this regimen was shown to improve the survival of patients with unresectable metastatic biliary cancers including GBCA.4

The histological examination for resected specimen for our patient confirmed the diagnosis of GBCA, 5.5cm, mixture of poorly differentiated adenocarcinoma and neuroendocrine carcinoma, pT3, pN1 (1/14), stage II. Our patient was elected not to receive adjuvant chemotherapy because of its histologic type.

Discussion

As symptoms associated with GBCA are in general vague and non-specific, most patients with GBCA presents when the disease is at an advanced stage and the majority of patients are diagnosed when the disease is beyond the borders of resection.5, 6 In fact, while obstructive jaundice is one of the most common symptoms associated with gallbladder cancer, it is well recognized as predictor of worse outcomes regardless of the types of treatment received.6 On the other hand, for most of patients with “incidental” GBCA, which is discovered by imaging study for unrelated disease, or cholecystectomy for suspected benign biliary symptoms, appropriate oncologic resection has a much greater impact on their long-term outcomes and radical surgery should not be discouraged for patients with locoregional disease without distant spread. Tumors beyond T2 (tumor invading to the muscular layer) are not be cured by simple cholecystectomy; 30% of patients staged T2 based on the primary cholecystectomy specimen (incidental diagnosis) were reported to have residual liver disease after reoperation with definitive resections and one third of them were found to have metastasis in the regional lymph nodes resected.2, 7

The extent of liver resection required depends on the extent of direct liver invasion and involvement of major hepatic vessels. While the wedge resection of gallbladder fossa should suffice to achieve negative margin for the tumor at the fundus with minimal liver invasion, when the right portal pedicle is involved by the tumor at the neck of gallbladder, right hemi-hepatectomy or even extended right hepatectomy may be necessary. When major liver resection is deemed necessary, preoperative portal vein embolization to increase the future remnant liver volume is often useful to decrease the risk of postoperative liver failure.8

Although the therapeutic role for regional lymphadenectomy is not yet established, systematic lymphadenectomy and histological evaluation are critical to provide accurate N staging. The study demonstrated that the outcomes for patients with N0 disease based on total lymph node count less than 6 was significantly worse than the outcome for those with N0 disease based on total lymph node count 6 or greater.2 Thus, it is recommended in current AJCC staging system that minimal 6 lymph nodes should be removed and examined histologically for accurate N stage. The optimal extent of lymphadenectomy has not been well defined, it is the author’s practice to remove the lymph nodes in the hepatoduodenal ligaments (#12), around the common hepatic artery (#8) and at the retropancreatic area (#13). The outcomes for patients with lymphadenopathy beyond this area, for example around the celiac artery or the aorta has been reported dismal. Radical resection will be unlikely beneficial for such patients and should not be performed.

The direct invasion to adjacent organs including duodenum, colon, and pancreas is not uncommon for advanced GBCA, and it is not considered as an absolute contraindication for resection. While some authors reported prolonged survival after enbloc organ resection,9, 10 such operations are often associated with higher risk of morbidity and mortality, and the application for aggressive radical operative for far advanced GBCA should be carefully considered individually.

Disclosures

Nothing to disclose.

Statement of Consent

The patient referred to in this video article has given their informed consent to be filmed and is aware that information and images will be published online.

Citations

  1. Henley SJ, Weir HK, Jim MA, Watson M, Richardson LC. Gallbladder Cancer Incidence and Mortality, United States 1999-2011. Cancer Epidemiol Biomarkers Prev 2015; 24(9):1319-26.
  2. Ito H, Ito K, D'Angelica M, Gonen M, Klimstra D, Allen P, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg 2011; 254(2):320-5.
  3. Davidson JTt, Jin LX, Krasnick B, Ethun CG, Pawlik TM, Poultsides GA, Idrees K, Weber SM, Martin RCG, Shen P, Hatzaras I, Maithel SK, Fields RC. Staging laparoscopy among three subtypes of extra-hepatic biliary malignancy: a 15-year experience from 10 institutions. J Surg Oncol 2019; 119(3):288-294.
  4. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362(14):1273-81.
  5. Ito H, Matros E, Brooks DC, Osteen RT, Zinner MJ, Swanson RS, Ashley SW, Whang EE. Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. J Gastrointest Surg 2004; 8(2):183-90.
  6. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol 2004; 11(3):310-5.
  7. Pawlik TM, Gleisner AL, Vigano L, Kooby DA, Bauer TW, Frilling A, Adams RB, Staley CA, Trindade EN, Schulick RD, Choti MA, Capussotti L. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg 2007; 11(11):1478-86; discussion 1486-7.
  8. Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nagino M. Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations. Dig Surg 2012; 29(1):23-9.
  9. Shirai Y, Ohtani T, Tsukada K, Hatakeyama K. Combined pancreaticoduodenectomy and hepatectomy for patients with locally advanced gallbladder carcinoma: long term results. Cancer 1997; 80(10):1904-9.
  10. Mizuno T, Ebata T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Ando M, Nagino M. Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. Br J Surg 2019; 106(5):626-635.